Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

2.6K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.6K
Esophageal Varices-II: Clinical Features and Management01:28

Esophageal Varices-II: Clinical Features and Management

832
Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
832
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

477
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
477
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

2.9K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.9K
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents01:24

Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents

2.3K
In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
2.3K
Peptic Ulcer Disease IV: Management01:26

Peptic Ulcer Disease IV: Management

732
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
732

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Decoding fibrosis: Transcriptomic and clinical insights via AI-derived collagen deposition phenotypes in MASLD.

Hepatology (Baltimore, Md.)·2026
Same author

In sphincter of Oddi patients, amelioration of pain is primarily associated with common bile duct dilation rather than hepatobiliary scintigraphy excretion time or alanine amino transferase - a single centre, retrospective study.

Clinical physiology and functional imaging·2026
Same author

Expert panel perspectives on improving the diagnosis and management of metabolic dysfunction-associated steatohepatitis in Denmark.

Scandinavian journal of gastroenterology·2026
Same author

LC-MS/MS of PEth in whole blood: implementation in routine clinical chemistry.

Practical laboratory medicine·2026
Same author

Liver support systems for adults with acute liver failure.

The Cochrane database of systematic reviews·2026
Same author

Magnetic resonance imaging-derived extracellular volume fraction mapping in metabolic dysfunction-associated steatotic liver disease reveals subclinical cardiac remodelling.

Scientific reports·2026

Related Experiment Video

Updated: Apr 20, 2026

Endoscopic Injection Sclerotherapy Assisted by Cyanoacrylate and Clips for Gastroesophageal Varices
04:09

Endoscopic Injection Sclerotherapy Assisted by Cyanoacrylate and Clips for Gastroesophageal Varices

Published on: June 13, 2025

1.8K

Tranexamic acid for upper gastrointestinal bleeding.

Cathy Bennett1, Sarah Louise Klingenberg, Ebbe Langholz

  • 1Centre for Technology Enabled Health Research (CTEHR), Coventry University, Coventry, UK.

The Cochrane Database of Systematic Reviews
|November 22, 2014
PubMed
Summary
This summary is machine-generated.

Tranexamic acid (TXA) may reduce mortality in upper gastrointestinal bleeding. Further research is needed to confirm this benefit due to trial limitations, but TXA shows potential for improved patient outcomes.

More Related Videos

Complete and Partial Aortic Occlusion for the Treatment of Hemorrhagic Shock in Swine
09:37

Complete and Partial Aortic Occlusion for the Treatment of Hemorrhagic Shock in Swine

Published on: August 24, 2018

11.1K
Upper-extremity Approach for Secondary Access in Transfemoral Transcatheter Aortic Valve Implantation
06:04

Upper-extremity Approach for Secondary Access in Transfemoral Transcatheter Aortic Valve Implantation

Published on: August 8, 2025

734

Related Experiment Videos

Last Updated: Apr 20, 2026

Endoscopic Injection Sclerotherapy Assisted by Cyanoacrylate and Clips for Gastroesophageal Varices
04:09

Endoscopic Injection Sclerotherapy Assisted by Cyanoacrylate and Clips for Gastroesophageal Varices

Published on: June 13, 2025

1.8K
Complete and Partial Aortic Occlusion for the Treatment of Hemorrhagic Shock in Swine
09:37

Complete and Partial Aortic Occlusion for the Treatment of Hemorrhagic Shock in Swine

Published on: August 24, 2018

11.1K
Upper-extremity Approach for Secondary Access in Transfemoral Transcatheter Aortic Valve Implantation
06:04

Upper-extremity Approach for Secondary Access in Transfemoral Transcatheter Aortic Valve Implantation

Published on: August 8, 2025

734

Area of Science:

  • Medical research
  • Clinical trials
  • Pharmacology

Background:

  • Tranexamic acid (TXA) is an antifibrinolytic agent used to reduce hemorrhage.
  • Previous reviews suggested TXA may decrease mortality in upper gastrointestinal bleeding (UGIB).
  • This updated review incorporates new trials to reassess TXA's efficacy and safety in UGIB.

Purpose of the Study:

  • To evaluate the effects of tranexamic acid compared to placebo, no intervention, or antiulcer drugs for upper gastrointestinal bleeding.
  • To assess primary outcomes including all-cause mortality, rebleeding, and adverse events.

Main Methods:

  • Systematic review and meta-analysis of randomized controlled trials (RCTs) published up to July 2014.
  • Searches included major databases (CENTRAL, MEDLINE, EMBASE, Science Citation Index).
  • Fixed-effect and random-effects models were used to analyze data, with risk ratios (RRs) and 95% confidence intervals (CIs).

Main Results:

  • Eight RCTs involving 1701 participants were included.
  • Tranexamic acid showed a statistically significant reduction in all-cause mortality (RR 0.60, 95% CI 0.42 to 0.87).
  • Rebleeding risk was not significantly reduced (RR 0.80, 95% CI 0.64 to 1.00), and no significant difference in thromboembolic events or transfusions was observed.

Conclusions:

  • Tranexamic acid appears to offer a potential mortality benefit in upper gastrointestinal bleeding.
  • High dropout rates in some trials necessitate further high-quality RCTs to confirm these findings.
  • Future research should focus on pragmatic trial designs with clear outcome definitions and appropriate controls.